New York, NY (PRWEB) July 24, 2012
Medmeme, LLC., a global leader in comprehensive, integrated medical and science information database platforms, has released the new syndicated TrendsmemeTM Report: Infectious Disease - Antimicrobials. It focuses on three indications—pneumonia, tuberculosis, and malaria - because they command the largest R&D effort and market in infectious diseases, and also they offer a window into issues relevant broadly across the therapeutic category. Based on the number of clinical trials reported in the Medmeme database, R&D for the broad field of pneumonia is the most active of the three indications. A major problem common to all three indications discussed in the report – and a threat relevant to the treatment of infectious diseases in general - is drug resistance. As more bacteria emerge that are resistant to currently available treatments for an indication, there is a significant need for novel new treatment approaches that work by different mechanisms, and therefore are likely to be effective for treatment of the resistant bacteria.
In spite of the competitive marketplace created by many generic versions of older drugs, healthcare stakeholders cite the critical need for new approaches to fight resistant bacteria and urge biopharma companies to work on this problem. The challenge also offers smaller firms new opportunities for success in the category, especially when partnering with larger firms. In addition to five Big Phama companies in this field - GlaxoSmithKline, Johnson & Johnson (through subsidiary Janssen), Novartis, Sanofi, and Pfizer as the most active – this TrendsmemeTM report also presents detailed analysis from the database about specific activities of other firms, including, among others: AstraZeneca, Bayer Healthcare, Forest Laboratories, Basilea Pharmaceutica, Cempra, Durata Therapeutics, Emergent BioSolutions, Otsuka Pharmaceutical, Paratek Pharmaceuticals, Ranbaxy Laboratories, Rib-X Pharmaceuticals, Sanaria, Sigma-Tau Pharmaceuticals, and Trius Therapeutics.
Medmeme CEO Mahesh Naithani addresses undertaking the challenge: “There’s no doubt that serious measures are necessary to overcome the challenge of a combination of low incentives to be in the infectious disease marketplace and the difficulty of finding the best treatment solutions for resistant bacteria. It’s a huge challenge. The effort of cooperation between government, science, and the industry is so important. I’m particularly referring to The Infectious Diseases Society of America, the physicians, scientists and other health care professionals who specialize in infectious diseases, working with the FDA to have it allow labeling antibiotics that fight drug-resistant strains of bacteria as “orphan drugs.” From this, companies may see these drugs on a faster track for approval and would be encouraged to join the effort in developing treatments. The new FDA guidelines on the design of antibiotic clinical trials are already having an impact on the pace of the progress for these innovative drugs too. And the partnering in Europe of GSK, Sanofi, AstraZeneca, Johnson & Johnson, and Basilea Pharmaceutica with leading scientists to form a consortium dedicated to sharing information and development data also addresses the lack of antibiotics in the pipeline. And not to forget the good work of NGO’s that will bring the successes of these efforts to the developing countries where need is so great. It’ll take all this, and more, to win the battle. We discuss these things in our report on infectious diseases.”
The syndicated TrendsmemeTM Report: Infectious Disease - Antimicrobials can be purchased separately, or, along with other MedMeme reports in the new series, at discounted pricing. To learn more, contact us, or see our website, http://www.medmeme.com/products/syndicated-reports/reports/trendsmeme-reports.
Yan Barshay, Executive Vice President
Ray Wright, Vice President, Sales
+ 1 508-278-4595